Company intelligence / Profile preview

NeuroPathways

West Chester, Pennsylvania, United Statesitd.cnyric.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Pathways Neuro Pharma has pivoted its pipeline to focus on rare pediatric neurological diseases, with a lead program targeting Juvenile Parkinson’s Disease using a proprietary AAV6.2FF gene therapy platform designed for long-lasting dopaminergic restoration without traditional agonist side effects. The approach aims for one-time administration with up to fifteen months of benefit and seeks regulatory incentives via Rare Pediatric Disease Designation.

Therapeutic areas: PsychiatryNeurology
Modalities: Gene therapy (AAV6.2FF platform)Non-dopaminergic neuroregulator restoration
Industry: Biotech

Partnerships

Financial partnership(s) announced in support of CNS-targeted gene therapies development, but specific partners unnamed as of Feb. 2025 press release.

Beyond the preview

Go deeper on NeuroPathways.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroPathways.

Explore the full profile